Compare GSK plc (GSK) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Harley-Davidson Inc — how do they compare? GSK plc trades at $46.82 (market cap $91.88B), while Harley-Davidson Inc trades at $26.75 (market cap $2.78B). The key difference: GSK plc is far larger — about 33.1× Harley-Davidson Inc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Harley-Davidson Inc for 91 Days on average.
| GSK | HOG | |
|---|---|---|
Market Cap | $91.88B | $2.78B |
Volume | 7,730,529 | 2,966,389 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $28.46 |
52-Week Low | $43.24 | $17.19 |
Typical Hold Time | 93 Days | 91 Days |
Enterprise Value | $111.88B | $3.20B |
Dividend Yield | 3.9% | 2.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Harley-Davidson (HOG) trades at $26.95, up 0.04% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $28.50. Recent Q2 2026 earnings beat expectations, but revenue has declined from $5.8B in 2022 to $4.5B in 2025, with net income margin falling to 7.57%. The company maintains a dividend and shows improved cash flow trends, though it faces headwinds from tariffs and a recent data breach investigation.
The stock presents a mixed outlook: valuation metrics like P/E of 14.97 and P/B of 0.9 suggest potential upside, but declining profitability and competitive pressures pose risks. Investor sentiment is cautious with 61% hold ratings, while institutional activity shows mixed positioning. Key catalysts include execution of the 'Back to the Bricks' strategy, though tariff exposures and softening demand remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
